Drug profile

The FDA adverse-event record for Fenbendazol Pellets

74 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Fenbendazol Pellets. See the species affected, top reactions, and outcomes below.

74
adverse-event reports
25.7%
death-coded share
Cattle
most-reported species
15
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
74
Total Reports
19
Deaths Reported
25.7%
Death Rate

Active Ingredients

Fenbendazol Pellets

Administration Routes

OralUnknownTopical

Species Affected

Cattle 33
Unknown 17
Pig 14
Horse 4
Dog 3
Other Birds 1
Sheep 1
Human 1

Most Affected Breeds

Cattle (other) 19
Unknown 18
Pig (unknown) 9
Crossbred Porcine/Pig 3
Holstein-Friesian also known as Holstein 3
Crossbred Bovine/Cattle 3
Cattle (unspecified) 3
Cattle (unknown) 2
Horse (unknown) 1
Other Birds (other) 1

Most Reported Reactions

Death 15
Lack of efficacy (endoparasite) - NOS 12
Product Defect, General 6
Product problem 6
Appearance, Abnormal 6
Lethargy (see also Central nervous system depression in 'Neurological') 5
Defect Unknown/Not Specified 4
UNPALATABLE 4
Lack of efficacy - NOS 4
Contamination, Mold 4
Milk production decrease 3
Not eating 3

Outcome Breakdown

Outcome Unknown
19 (28.4%)
Died
17 (25.4%)
Recovered/Normal
16 (23.9%)
Ongoing
13 (19.4%)
Euthanized
2 (3.0%)

Fenbendazol Pellets Adverse Event Insights

74 reports name Fenbendazol Pellets; 19 recorded a death outcome (25.7% of reported events, not a population-level mortality rate). Active ingredient: Fenbendazol Pellets. Administration routes: Oral, Unknown, Topical.

By species: Cattle (33 reports), Unknown (17 reports), Pig (14 reports). By breed: Cattle (other) (19), Unknown (18), Pig (unknown) (9).

Leading clinical signs: Death (15), Lack of efficacy (endoparasite) - NOS (12), Product Defect, General (6), Product problem (6). Outcome, 67 coded reports: Outcome Unknown leads at 28.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.